Nancy Aitcheson

Dr. Nancy Aitcheson

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
KDKelly E Dyer
Kelly E Dyer
RRRebecca Russell
Rebecca Russell
RNRayek Nafiz
Rayek Nafiz
ABAngela Burdick-McPhee
Angela Burdick-McPhee
JOJean O’nEal
Jean O’nEal
JTJessie Torgersen
Jessie Torgersen
Background: People with substance use disorders (SUDs) are at higher risk for infectious diseases (IDs). Co-locating ID screening services within inpatient SUD treatment programs may decrease barriers to care; however, the impact of such screening has not been evaluated. Methods: We conducted an effectiveness study evaluating comprehensive ID screening within an 18-bed inpatient SUD program. During usual care (September 2021–June 2022), ID screening was completed at the discretion of the admitting psychiatrist. During the intervention (September 2022–June 2023), an ID-trained nurse met with patients to support completion of screening for HIV, viral hepatitis (hepatitis A [HAV], B [HBV], and C [HCV]), latent tuberculosis [LTBI], and sexually transmitted infections [STI]. Hepatitis vaccinations, HIV preexposure prophylaxis, and/or ID treatments were offered during admission. Results: Demographics were similar between the groups (n = 261, usual care; n = 207, intervention). Screening for ≥1 ID increased significantly during the intervention (60.2% vs 90.8%, P < .001), with the greatest increases in HAV (6.1% vs 90.3%, P < .001), HBV (8.8% vs 91.3%, P < .001), and LTBI (1.9% vs 67.8%, P < .001). HAV and HBV vaccinations increased from 0% to 58% and 71%, respectively. HCV viremia was identified in 15 usual care and 19 intervention patients, of whom 0% and 36.8% initiated direct-acting antiviral therapy within 2 weeks of testing. STIs were identified in 9.2% and 13.5% (P = .09) of the patients in the usual care and intervention groups. Conclusions: Comprehensive ID screening within inpatient SUD programs can increase uptake of testing and facilitate low-barrier delivery of preventive and therapeutic treatment.

18 January 2024 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Open access
NANancy Aitcheson
Nancy Aitcheson
ESEmma Sacks
Emma Sacks
TNTichaona H. MBChB Nyamundaya
Tichaona H. MBChB Nyamundaya
CMCephas Pmp Muchuchuti
Cephas Pmp Muchuchuti
JCJennifer Cohn
Jennifer Cohn
Background: Routine birth testing of HIV-exposed infants (HEI) using point of care (POC) nucleic acid testing may allow for earlier diagnosis and treatment of infants living with HIV, but more data are needed on retention in care for those diagnosed at birth and re-testing for those with a negative HIV birth test. Methods: POC birth testing (within 48 hours of birth) was offered to all HEI born at 10 public maternities in Zimbabwe from November 2018 to July 2019. Data were abstracted from routine registers, including information on re-testing at 6–8 weeks for infants testing HIV-negative at birth and 6-month retention in care among infants diagnosed with HIV at birth. Results: Of 2854 eligible HEIs, 2806 (98.3%) received POC HIV birth testing. Thirty-nine infants with HIV were identified (1.4%), and 23 (59%) were started on antiretroviral therapy (ART). Twenty infants (51%) remained on ART at 6 months. Of the 2694 infants who tested negative at birth, 1229 (46.5%) had a documented retest at 6–8 weeks. 7 (0.6%) of those infants tested HIV-positive. Conclusions: The uptake of POC birth testing was high in study facilities, but low rates of ART initiation after a positive birth test, despite high retention on ART through 6 months, diminish the impact of POC birth testing and must be addressed. Among infants who tested negative at birth, rates of testing at 6–8 weeks of life (46%) were slightly lower than national rates of testing at the same age without a birth test (56%) during the study period. Improving infant HIV testing rates at 6–8 weeks, regardless of birth testing, should be a priority.

16 July 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
ARAaron Richterman
Aaron Richterman
COCaroline O’bRien
Caroline O’bRien
FGFatemeh Ghadimi
Fatemeh Ghadimi
ESElijah Sumners
Elijah Sumners
AFAndre Ford
Andre Ford
FMFlorence Momplaisir
Florence Momplaisir
Background: The 2022 mpox outbreak serves as an important example of a rapidly emerging epidemic that disproportionately affected marginalized populations. Despite the availability of a preventive vaccine, its deployment ultimately fell short of reaching the populations at greatest risk. Therefore, we sought to evaluate the vaccination campaign from the perspectives of key stakeholders. Methods: We conducted semistructured interviews to assess knowledge and perceptions of mpox, as well as barriers and facilitators to vaccine uptake in Philadelphia. We recruited health care clients and community members who were eligible for mpox vaccination and health care workers and community-based organization staff involved in vaccination efforts. We used purposeful selection to ensure inclusion of people with HIV. We used an integrated analysis approach that combined modified grounded theory and implementation science constructs. Results: We interviewed 21 health care clients, 9 community members, 10 health care workers, and 3 community-based organization staff after the primary mpox response in 2022 between February 2023 and October 2024. Participants varied in their knowledge and perceptions of mpox risk, primarily varying based on the perceived importance of sexual identity vs sexual behaviors. They generally believed that at-risk individuals should be vaccinated. Participants reported trusting mpox information from sources they trusted for other health information, such as health departments or knowledgeable members of social networks. Most participants expressed concern about inequitable distribution of the vaccine. Commonly reported facilitators to vaccination included one's own risk perception, technological literacy, co-locating vaccinations with existing clinical and social spaces, and outreach through trusted health-, community-, and social network–based resources. Knowledge, administrative (eg, difficulty signing up), and logistical (eg, limited clinic hours) barriers to vaccine access were thought to exacerbate inequities. Conclusions: While an effective mpox vaccine was a key asset in the response, barriers related to availability, accessibility, awareness, and logistical constraints limited its reach to those at highest risk.

Verified
Journal Article
Open access
PDF file
LCLissette R Chang
Lissette R Chang
CGCristine Gutierrez
Cristine Gutierrez
JRJose Rodas
Jose Rodas
NANancy Aitcheson
Nancy Aitcheson
NFNasim Farach
Nasim Farach
BPBenjamin Ryan Phelps
Benjamin Ryan Phelps
To better understand recent adolescent (10–19 years) HIV trends in Central America, we analyzed routine data from countries supported by the United States President’s Emergency Plan for AIDS Relief (PEPFAR): Guatemala, El Salvador, Honduras, Panama, and Nicaragua, over the period from October 2020 to September 2024. Key PEPFAR indicators included HIV testing, HIV positivity rates, new treatment initiations, advanced HIV disease (AHD) at diagnosis, viral load coverage (VLC), viral load suppression (VLS), and multi-month dispensing (MMD) uptake for children and adolescents living with HIV (CALHIV) from 10–19 years of age. Since October 2020, the number of HIV tests conducted among adolescents has increased; however, the positivity rate has remained stable at approximately 2%. The number of adolescents initiating treatment increased by 21%. At the same time, VLS has shown steady regional improvement (from 73% to 90%), though VLC is a persistent challenge (80%). Treatment interruption rates have been relatively stable, fluctuating between 2% and 3%. Advanced HIV is high in adolescents new to treatment (34%), especially among females (40%), though cluster of differentiation 4 (CD4) testing at diagnosis has only been collected recently and coverage is not complete. The high prevalence of AHD among adolescents underscores the need to reinforce earlier and more targeted interventions for adolescents, especially in countries with greater HIV prevalence such as Panama and Guatemala.

27 August 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
NANancy Aitcheson
Nancy Aitcheson
YLYun Li
Yun Li
YFYixuan Feng
Yixuan Feng
COCaroline S O'BRien
Caroline S O'BRien
MKMoira Kyweluk
Moira Kyweluk
FMFlorence Momplaisir
Florence Momplaisir
Background: Transgender individuals face disproportionate HIV burden yet experience significant barriers to accessing biomedical HIV prevention. We assessed awareness, experience, and willingness among trans adults to use pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) when integrated with telehealth-delivered gender-affirming hormone care (GAC). Methods: We conducted a cross-sectional survey of clients receiving GAHC via a national subscription-based telehealth platform between October 2023 and January 2024. Using stratified sampling to ensure inclusion of transgender men (TGM) and those residing in rural areas, we assessed PrEP/PEP awareness, prior use, barriers, and willingness to use these services if recommended by their GAC provider. Multivariable logistic regression identified factors associated with stated willingness (yes/no). Results: Among 387 respondents (from 2506 survey invitations, 15.4% response rate), 54.8% identified as transgender women (TGW), 45% were between the ages of 18 and 25, and 74% identified as white, and 13% resided in rural areas. Pre-exposure prophylaxis awareness was moderate among TGW (56%) and TGM (69%), while PEP awareness was 24% among TGW and 31% among TGM. Only 2% of TGW were using PrEP (0% of TGM), and 0% had used PEP. Despite limited prior utilization, 67% expressed willingness to use PrEP and 66% willingness to use PEP if recommended by their GAC provider. Public insurance (vs private) and self-reported HIV worry (vs not worried) were associated with willingness to use both PrEP (public insurance: aOR 3.64, P = .022; HIV worry: aOR 2.57, P = .002) and PEP (public insurance: aOR 3.48, P = .032; HIV worry: aOR 2.41, P = .004). Prior awareness of PEP was also associated with willingness to use it (aOR 2.06, 95% CI 1.08–3.94, P = .030). Conclusions: Among clients of a subscription-based telehealth platform, stated acceptability of integrated PrEP/PEP services was high regardless of gender identity or geography. Limited awareness, cost concerns, and the large gap between awareness and utilization require further attention to realize the potential benefits of biomedical HIV prevention integration into telehealth GAC.

10 March 2026 in AIDS Patient Care and STDs
Verified
Journal Article
Closed access
COCaroline S. O’BRien
Caroline S. O’BRien
MKMoira Kyweluk
Moira Kyweluk
NDNadia Dowshen
Nadia Dowshen
FMFlorence Momplaisir
Florence Momplaisir
NANancy Aitcheson
Nancy Aitcheson
Preexposure prophylaxis (PrEP) and postexposure prophylaxis (PEP) continue to be underutilized among transgender people despite elevated HIV incidence in this population. Many transgender individuals report that their gender-affirming care (GAC) is their highest health care priority, and an increasing number seek this care via telehealth. We sought to understand clinician perspectives and needs regarding integrating HIV PrEP and HIV PEP into GAC in a telehealth model. We conducted semi-structured interviews with clinicians who self-identified as providing gender-affirming care via telehealth. We used the transdisciplinary approach to evidence-based practice to inform our interview guide and codebook and used thematic analysis to analyze the resulting data. Among our 20 participants interviewed in December 2023 and January 2024, there was enthusiasm to offer trans patients biomedical HIV prevention within GAC. Participants were most comfortable managing oral PrEP. Identified barriers include lab work cadence and issues getting medication to patients (especially the drugs for HIV PEP). PrEP navigators, patient self-advocacy, and trusting patient–clinician relationships were identified as facilitators of co-location. A clinician’s ability to offer a transgender patient both GAC and PrEP/HIV PEP in the same telehealth visit is a promising strategy to tackle the disproportionate incidence of HIV among trans people. Trusting clinical relationships facilitated by the provision of GAC can be utilized to more accurately assess HIV risk and more effectively offer PrEP and HIV PEP.